Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Sell
50
STRO Quote, Financials, Valuation and Earnings
Last price:
$12.31
Seasonality move
:
-14.43%
Day range:
$11.88 - $13.30
52-week range:
$5.23 - $21.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
3.01x
P/B ratio:
1.64x
Volume:
156K
Avg. volume:
120.4K
1-year change:
-37.28%
Market cap:
$100.1M
Revenue:
$62M
EPS (TTM):
-$17.75
Analysts' Opinion
-
Consensus RatingSutro Biopharma, Inc. has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 4 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $21.00, Sutro Biopharma, Inc. has an estimated upside of 78.72% from its current price of $12.23.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $8.00 representing 100% downside risk from its current price of $12.23.
Fair Value
-
According to the consensus of 8 analysts, Sutro Biopharma, Inc. has 78.72% upside to fair value with a price target of $21.00 per share.
STRO vs. S&P 500
-
Over the past 5 trading days, Sutro Biopharma, Inc. has overperformed the S&P 500 by 0.63% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Sutro Biopharma, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Sutro Biopharma, Inc. has grown year-over-year revenues for 3 quarters straight. In the most recent quarter Sutro Biopharma, Inc. reported revenues of $9.7M.
Earnings Growth
-
Sutro Biopharma, Inc. earnings have been falling on a year-over-year basis for 2 quarters in a row. In the most recent quarter Sutro Biopharma, Inc. reported earnings per share of -$6.70.
Enterprise value:
160M
EV / Invested capital:
--
Price / LTM sales:
3.01x
EV / EBIT:
--
EV / Revenue:
1.51x
PEG ratio (5yr expected):
0.00x
EV / Free cash flow:
-0.71x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$98.1M
Return On Assets:
-66.39%
Net Income Margin (TTM):
-205.18%
Return On Equity:
-10195.04%
Return On Invested Capital:
-101.26%
Operating Margin:
-401.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $48.6M | $161M | $105.6M | $8.5M | $9.7M | |
| Gross Profit | $40.1M | $153.9M | $98.1M | $6.7M | $7.8M | |
| Operating Income | -$181.7M | -$130M | -$136.6M | -$67.9M | -$38.9M | |
| EBITDA | -$173.1M | -$123M | -$129M | -$66.1M | -$37M | |
| Diluted EPS | -$2.91 | -$1.62 | -$17.75 | -$0.59 | -$6.70 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $250.7M | $346.6M | $381.3M | $405.8M | $182.1M | |
| Total Assets | $371.5M | $400.7M | $431.7M | $451.8M | $209.7M | |
| Current Liabilities | $35.5M | $58.3M | $73.6M | $131.3M | $71.9M | |
| Total Liabilities | $87.9M | $171M | $319.4M | $340.6M | $296.9M | |
| Total Equity | $283.6M | $229.7M | $112.3M | $111.2M | -$87.3M | |
| Total Debt | $57M | $50.3M | $32M | $189.6M | $219.6M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$149.6M | -$105.7M | -$222.5M | -$64.5M | -$38.2M | |
| Cash From Investing | -$18.3M | $107.5M | $113.8M | $147.3M | $40M | |
| Cash From Financing | $152.9M | $91M | $84K | $1M | $102K | |
| Free Cash Flow | -$155.8M | -$109.2M | -$225.1M | -$65.3M | -$38.4M | |
STRO
Sector
Market Cap
$100.1M
$28.3M
Price % of 52-Week High
54.65%
51.99%
Dividend Yield
0%
0%
Shareholder Yield
-10.55%
-1.59%
1-Year Price Total Return
-39.74%
-17.41%
Beta (5-Year)
1.526
0.495
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$11.54
200-day SMA
Buy
Level
$8.78
Bollinger Bands (100)
Buy
Level
8.31 - 10.63
Chaikin Money Flow
Sell
Level
-7.5M
20-day SMA
Buy
Level
$10.69
Relative Strength Index (RSI14)
Buy
Level
66.31
ADX Line
Buy
Level
23.72
Williams %R
Sell
Level
-14.8631
50-day SMA
Buy
Level
$9.70
MACD (12, 26)
Buy
Level
0.69
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
596.4K
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-3.7959)
Sell
CA Score
(Annual)
Level (-4.171)
Buy
Beneish M-Score
(Annual)
Level (-3.7351)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (4.7616)
Sell
Piotroski F Score
(Annual)
Level (2)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, STRO has received 4 Buy ratings 4 Hold ratings, and 0 Sell ratings. The STRO average analyst price target in the past 3 months is $21.00.
-
Where Will Sutro Biopharma, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Sutro Biopharma, Inc. share price will rise to $21.00 per share over the next 12 months.
-
What Do Analysts Say About Sutro Biopharma, Inc.?
Analysts are divided on their view about Sutro Biopharma, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Sutro Biopharma, Inc. is a Sell and believe this share price will drop from its current level to $8.00.
-
What Is Sutro Biopharma, Inc.'s Price Target?
The price target for Sutro Biopharma, Inc. over the next 1-year time period is forecast to be $21.00 according to 8 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is STRO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Sutro Biopharma, Inc. is a Leans Bullish. 4 of 8 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of STRO?
You can purchase shares of Sutro Biopharma, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Sutro Biopharma, Inc. shares.
-
What Is The Sutro Biopharma, Inc. Share Price Today?
Sutro Biopharma, Inc. was last trading at $12.31 per share. This represents the most recent stock quote for Sutro Biopharma, Inc.. Yesterday, Sutro Biopharma, Inc. closed at $12.23 per share.
-
How To Buy Sutro Biopharma, Inc. Stock Online?
In order to purchase Sutro Biopharma, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get STRO Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
STRO
Sector
P/E ratio
--
24.24x
PEG ratio
0.00x
-0.01x
P/B ratio
1.64x
1.84x
Price / LTM sales
3.01x
1.60x
Growth Metrics
STRO
Sector
Revenue growth
13.77%
4.6%
Earnings growth
-1026.69%
10.71%
Revenue (5-year growth)
7.74%
6.45%
Earnings forecast
-$4.43
-$0.19
Profitability
STRO
Sector
Profitability FY 2024
$54.8M
$3.5M
Return on invested capital
-101.26%
-32.04%
Return on assets
-66.39%
-28.44%
Return on equity
-10195.04%
-38.09%
Earnings Date
Last Earnings Date
Aug
11
Next Earnings Date
Jan
10
Estimated Next Earnings Date
Apr
11
Balance Sheet
STRO
Sector
Total cash
$167.6M
$26.1M
Short term investments
$126.6M
$25.7M
Total assets
$387.2M
$76.4M
Long term debt
$219.6M
$3.2M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
65
RGC alert for Jan 10
Regencell Bioscience Holdings Ltd. [RGC] is up 10.55% over the past day.
Sell
50
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
